-

04:39:39 AM

Latest OCX Stock Market News

OCX - OncoCyte Corp

06/15/21 8:03 AM

NYSE : OCX

EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings

Echelon Diagnostics, Inc. , a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points

RHEA-AI

neutral

06/03/21 8:00 AM

Nasdaq : OCX

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies If Successful, Oncocyte’s DetermaIO Test for Immune Therapy Response Prediction Will Be Validated in a Fifth Tumor

RHEA-AI

positive

06/01/21 8:00 AM

Nasdaq : OCX

Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer

Oncocyte Corporation (NASDAQ: OCX), a molecular

RHEA-AI

very positive

05/17/21 4:01 PM

Nasdaq : OCX

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer utility of DetermaIO for immunotherapy response prediction – -DetermaIO pilot projects secured from three

RHEA-AI

neutral

05/06/21 8:00 AM

Nasdaq : OCX

Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.

Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s newly acquired IP creates solid foundation for blood-based monitoring for cancer recurrence as well as

RHEA-AI

neutral

05/04/21 4:01 PM

Nasdaq : OCX

Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17

Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results

RHEA-AI

neutral

04/28/21 4:31 PM

Nasdaq : OCX

Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting

Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at

RHEA-AI

neutral

04/19/21 8:00 AM

Nasdaq : OCX

Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the selection of appropriate immune therapies and monitoring for treatment response in real time allowing

RHEA-AI

neutral

04/14/21 9:02 AM

Nasdaq : OCX

Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors

Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will host a key opinion leader (KOL) call on

RHEA-AI

neutral

04/10/21 1:31 PM

Nasdaq : OCX

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of

RHEA-AI

neutral

1 2 3 4 5 6 Next

OCX Data

industryIn-Vitro Diagnostic Substance Manufacturing
websitewww.oncocyte.com
ceo
security nameOncoCyte Corp
issue typecs
sectorManufacturing
sic code2835
employees
tagsHealth Technology,Medical Specialties,Manufacturing,In-Vitro Diagnostic Substance Manufacturing
address15 Cushing
address2
stateCalifornia
cityIrvine
zip92618
countryUS
phone19494097600

OCX Description:

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.